Monoclonal Antibodies as Long-Acting Products: What Are We Learning From Human Immunodeficiency Virus (HIV) and Coronavirus Disease 2019 (COVID-19)?
Monoclonal Antibodies as Long-Acting Products: What Are We Learning From Human Immunodeficiency Virus (HIV) and Coronavirus Disease 2019 (COVID-19)?
复制标题
DOI：
10.1093/cid/ciac751
复制
发表时间：
2022-11-21
影响因子：
11.8
通讯作者：
Kuritzkes, Daniel R.
中科院分区：
文献类型：
--
作者：
Caskey, Marina;Kuritzkes, Daniel R.
针对人类免疫缺陷病毒（HIV）的广泛中和抗体有望成为预防和治疗HIV的长效药物。讨论了进展和挑战。从治疗和预防COVID-19的单克隆抗体的开发中可以吸取教训。针对人类免疫缺陷病毒（HIV）的广泛中和抗体有望成为预防和治疗HIV的长效药物。讨论了迄今取得的进展和未来的挑战。我们可以从开发单克隆抗体来治疗和预防2019冠状病毒病（COVID-19）中吸取教训。
Broadly neutralizing antibodies directed against human immunodeficiency virus (HIV) offer promise as long-acting agents for prevention and treatment of HIV. Progress and challenges are discussed. Lessons may be learned from the development of monoclonal antibodies to treat and prevent COVID-19.Broadly neutralizing antibodies directed against human immunodeficiency virus (HIV) offer promise as long-acting agents for prevention and treatment of HIV. Progress to date and future challenges are discussed. Lessons may be learned from the development of monoclonal antibodies to treat and prevent coronavirus disease 2019 (COVID-19).